

# Product Specifications

Custom Oligo Synthesis, antisense oligos, RNA oligos, chimeric oligos, Fluorescent dyes, Affinity Ligands, Spacers & Linkers, Duplex Stabilizers, Minor bases, labeled oligos, Molecular Beacons, siRNA, phosphonates Locked Nucleic Acids (LNA); 2'-5' linked Oligos

[26-6624-XX]

# Oligo Modifications

For research use only. Not for use in diagnostic procedures for clinical purposes.

# Lignoceryl C24 (3') LMO

Category **Antisense** Modification Code 3-Lig-C24 Reference Catalog Number 26-6624 5 Prime Ν C6 Linker 3 Prime Υ HO 3 Internal Ν Molecular Weight(mw) 544.77 3'-Lignoceryl (C24) LMO www.Oligo-5'

We offer custom oligo synthesis of your designed sequences for conjugation to lignoceric acid and palmitic acid for MULTI-seq: sample multiplexing for single-cell RNA sequencing **YIELD** Approximate polyacrylamide gel purified yield for various scales are given below for an oligo below 50mer.

Yield given below are for oligos shorter than 50mer. Please see longer oligos yield at this link Long Oligo Typical Yield.

- ~2 nmol final yield for 50 nmol scale synthesis.
- ~8 nmol final yield for 200 nmol scale synthesis.
- ~25 nmol final yield for 1 umol scale synthesis
- ~45nmol final yield for 2 umol scale synthesis ~110nmol final yield for 5 umol scale synthesis
- ~180 nmol final yield for 10 umol scale synthesis
- ~260 nmol final yield for 15 umol scale synthesis
- Click here to order stock MULTI-Seq LMO Lig-Anchor oligos.

Lipid modified oligos (LMO; lignoceric, palmitic, cholesterol etc.); These LMO rapidly and stably incorporate into the plasma membrane of live cells by step-wise assembly. McGinnis, C. et al. (1) adapted LMOs into MULTI-seq: scRNA-seq (single-cell) and snRNA-seq (single-nucleus) sample multiplexing using lipid-tagged indices. MULTI-seq localizes sample barcodes to live cells and nuclei regardless of species or genetic background while preserving cell viability and endogenous gene expression patterns.

MULTI-Seq LMO Lig Anchor and MULTI-Seq LMO Palm Co-Anchor oligos are lignoceric and palmitic acid conjugated oligos as described by McGinnis, C. et al. (1)

1. McGinnis, C. et al. MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. Nat. Methods 16, 619-626 (2019).

Lignoceric acid, or tetracosanoic acid, is long C24 chain saturated fatty acid. It is found in wood tar, various cerebrosides, and in small amounts in most natural fats. The fatty acids of peanut oil contain small amounts of lignoceric acid. This fatty acid is also a byproduct of lignin production.

Oligonucleotides are predominantly hydrophilic species and require help in permeating cell membranes. One strategy to improve cellular uptake of therapeutic oligonucleotides is to conjugate them with non-toxic, lipophilic molecules. Gene Link offers cholesteryl TEG, alpha-tocopherol and stearyl labelling of oligonucleotides and this strategy has proved to be useful for delivering therapeutic oligonucleotides to a broad distribution of targets.



### **Stearyl Modification**

Stearyl Modification is C18 lipid, it is an economical and effective carrier molecule. We envisage that the 5'-stearyl group will become a favored lipophilic carrier for experimentation with synthetic oligonucleotides.

#### **Cholesterol TEG Modification**

Cholesterol TEG Modification is a lipophilic modification aiding in cellular delivery. The TEG liker arm facilitates solubility issues of the oligo making it soluble in aqueous buffers.

### alpha-tocopherol TEG Modification

Similar to cholesterol TEG, alpha-tocopherol (vitamin E) is both lipophilic and non-toxic even at high doses so would be an excellent candidate as a lipophilic carrier for oligonucleotides. The TEG liker arm facilitates solubility issues of the oligo making it soluble in aqueous buffers.

#### **GalNAc**

A more directed approach to the delivery of therapeutic oligonucleotides specifically to the liver has been to target the asialoglycoprotein receptor (ASGPR) using a suitable glycoconjugate. Indeed, ASGPR is the ideal target for delivery of therapeutic oligonucleotides to the liver since it combines tissue specificity, high expression levels and rapid internalization and turnover. The use of oligonucleotide glycoconjugates has led to significant advances in therapeutic delivery as evidenced by the work of Alnylam Pharmaceuticals which has developed multivalent N-acetylgalactosamine (GalNAc) conjugated siRNAs that bind at nanomolar levels to ASGPR (1). A similar strategy has been applied at lonis Pharmaceuticals directed at the development of antisense oligonucleotide therapeutics (2).

The GalNAc ligand originally used by Alnylam is the triantennary ligand would seem to lend itself to formation by post synthesis conjugation to the 3' terminus but a complex trivalent GalNAc support would also be perfectly applicable, if challenging to produce. However, an alternative approach using a monovalent GalNAc support with two additions of a monovalent GalNAc phosphoramidite was also described and yielded a trivalent GalNAc structure. This (1+1+1) trivalent GalNAc structure led to GalNAc modified siRNA oligos with potency equal to the equivalent siRNA with the triantennary GalNAc ligand both in vitro and in vivo.

A further report on antisense oligonucleotides demonstrated (4) the effectiveness of modifying at the 5' terminus using monovalent GalNAc ligands. Up to five GalNAc monomers were added in a serial manner (Figure 3) and it was shown that activity of the antisense oligonucleotides improved as the number of GalNAc units increased. The authors also showed that phosphodiester linkages between the GalNAc units were preferable to phosphorothioate linkages in their testing (4).

## **Recommended Further Reading**

N-acetylgalactosamine (GalNAc) Oligo Application Note: Glen Report 29.14: N-acetylgalactosamine (GalNAc) Oligonucleotide Conjugates

References. Adapted from Glen Research Reports. http://www.glenresearch.com/GlenReports/GR29-14.html

- 1. J.K. Nair, et al., J Am Chem Soc, 2014, 136, 16958-61.
- 2. T.P. Prakash, et al., Bioorganic & Medicinal Chemistry Letters, 2015, 25, 4127-4130.
- 3. K.G. Rajeev, et al., Chembiochem, 2015, 16, 903-8.
- 4. T. Yamamoto, M. Sawamura, F. Wada, M. Harada-Shiba, and S. Obika, Bioorganic & Medicinal Chemistry, 2016, 24, 26-32.

